221 related articles for article (PubMed ID: 11020406)
41. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
[TBL] [Abstract][Full Text] [Related]
42. Brimonidine.
Bakheit AH; Alomar AM; Darwish H; Alkahtani HM
Profiles Drug Subst Excip Relat Methodol; 2023; 48():1-37. PubMed ID: 37061271
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.
Wilhelm B; Lüdtke H; Wilhelm H;
Graefes Arch Clin Exp Ophthalmol; 2006 May; 244(5):551-8. PubMed ID: 16151785
[TBL] [Abstract][Full Text] [Related]
44. Anterior uveitis associated with latanoprost.
Fechtner RD; Khouri AS; Zimmerman TJ; Bullock J; Feldman R; Kulkarni P; Michael AJ; Realini T; Warwar R
Am J Ophthalmol; 1998 Jul; 126(1):37-41. PubMed ID: 9683147
[TBL] [Abstract][Full Text] [Related]
45. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
46. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Osborne SA; Montgomery DM; Morris D; McKay IC
Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
[TBL] [Abstract][Full Text] [Related]
47. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
48. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
49. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
50. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Toris CB; Camras CB; Yablonski ME
Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
[TBL] [Abstract][Full Text] [Related]
51. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
[TBL] [Abstract][Full Text] [Related]
52. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
53. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
54. Brimonidine--an alpha 2-agonist for glaucoma.
Med Lett Drugs Ther; 1997 Jun; 39(1002):54-5. PubMed ID: 9198727
[No Abstract] [Full Text] [Related]
55. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization.
Ferencz JR; Gilady G; Harel O; Belkin M; Assia EI
Graefes Arch Clin Exp Ophthalmol; 2005 Sep; 243(9):877-80. PubMed ID: 15785924
[TBL] [Abstract][Full Text] [Related]
56. Bilateral granulomatous uveitis in an elderly female.
Kattige J; Konana VK; Babu K
Indian J Ophthalmol; 2019 Sep; 67(9):1391. PubMed ID: 31436179
[No Abstract] [Full Text] [Related]
57. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
58. The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
Ma YR; Lee BH; Yang KJ; Park YG
Korean J Ophthalmol; 1999 Dec; 13(2):78-84. PubMed ID: 10761402
[TBL] [Abstract][Full Text] [Related]
59. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
60. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
Lee DA; Gornbein J; Abrams C
J Ocul Pharmacol Ther; 2000 Feb; 16(1):3-18. PubMed ID: 10673126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
